687.00
-29.00
(-4.05%)
At close: January 2 at 10:13:08 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,847,100.00
13,117,200.00
12,172,900.00
16,071,700.00
8,497,100.00
Cost of Revenue
1,922,100.00
1,815,800.00
1,560,400.00
2,437,500.00
1,119,900.00
Gross Profit
11,925,000.00
11,301,400.00
10,612,500.00
13,634,200.00
7,377,200.00
Operating Expense
7,834,400.00
7,068,200.00
5,618,500.00
4,639,400.00
3,800,600.00
Operating Income
4,090,600.00
4,233,200.00
4,994,000.00
8,994,800.00
3,576,600.00
Net Non Operating Interest Income Expense
614,000.00
422,900.00
100,700.00
-11,500.00
-56,900.00
Other Income Expense
264,800.00
-456,800.00
-235,900.00
342,500.00
290,700.00
Pretax Income
4,969,400.00
4,199,300.00
4,858,800.00
9,325,800.00
3,810,400.00
Tax Provision
314,900.00
245,700.00
520,400.00
1,250,500.00
297,200.00
Net Income Common Stockholders
4,654,500.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Diluted NI Available to Com Stockholders
4,654,500.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Basic EPS
43.25
37.05
40.51
76.40
32.65
Diluted EPS
40.43
34.77
38.22
71.97
30.52
Basic Average Shares
107,600.00
106,700.00
107,100.00
105,700.00
107,600.00
Diluted Average Shares
115,125.00
113,700.00
113,500.00
112,200.00
115,100.00
Total Operating Income as Reported
3,973,400.00
4,047,100.00
4,738,900.00
8,946,800.00
3,576,600.00
Total Expenses
9,756,500.00
8,884,000.00
7,178,900.00
7,076,900.00
4,920,500.00
Net Income from Continuing & Discontinued Operation
4,654,500.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Normalized Income
4,412,099.59
4,364,628.80
4,556,917.10
7,782,159.00
3,513,200.00
Interest Income
677,000.00
495,900.00
160,100.00
45,800.00
--
Interest Expense
63,000.00
73,000.00
59,400.00
57,300.00
56,900.00
Net Interest Income
614,000.00
422,900.00
100,700.00
-11,500.00
-56,900.00
EBIT
5,032,400.00
4,272,300.00
4,918,200.00
9,383,100.00
3,867,300.00
EBITDA
5,501,900.00
4,693,300.00
5,259,600.00
9,669,300.00
4,103,200.00
Reconciled Cost of Revenue
1,922,100.00
1,815,800.00
1,560,400.00
2,437,500.00
1,119,900.00
Reconciled Depreciation
469,500.00
421,000.00
341,400.00
286,200.00
235,900.00
Net Income from Continuing Operation Net Minority Interest
4,654,500.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Total Unusual Items Excluding Goodwill
258,800.00
-436,800.00
-244,700.00
338,500.00
--
Total Unusual Items
258,800.00
-436,800.00
-244,700.00
338,500.00
--
Normalized EBITDA
5,243,100.00
5,130,100.00
5,504,300.00
9,330,800.00
4,103,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
16,399.59
-25,771.20
-26,182.90
45,359.00
--
12/31/2020 - 11/27/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
0K4.F Akero Therapeutics, Inc.
25.36
+0.71%
0MGB.IL Genmab A/S
1,601.75
+0.28%
1VT.BE Viking Therapeutics Inc
38.60
-3.67%
ORKA Oruka Therapeutics, Inc.
15.72
-17.31%
LIPO Lipella Pharmaceuticals Inc.
2.9000
-8.52%
HRMY Harmony Biosciences Holdings, Inc.
33.86
-1.94%
URGN UroGen Pharma Ltd.
10.24
-7.25%
PCVX Vaxcyte, Inc.
81.08
+0.02%
MRUS Merus N.V.
43.85
+3.84%
KOD Kodiak Sciences Inc.
8.32
-9.57%